Primary Sjögren’s syndrome presenting with non-diffuse membranoproliferative glomerulonephritis-like lesions in cryoglobulinemic glomerulonephritis: a case report

Zhi-Yu Duan, Guangyan Cai, FengKun Chen, Xuanli Tang, Xu Zhang, Yali Ren, Yan SongFrontiers in Immunology 2025 · DOI

This case report, published in Frontiers in Immunology, details a unique clinical presentation of Primary Sjögren’s syndrome (pSS). While kidney involvement is a known complication of pSS, the authors describe the first reported instance of non-diffuse membranoproliferative glomerulonephritis (MPGN) triggered by a pulmonary infection, challenging the standard diagnostic expectation that MPGN must present as a diffuse, global change.

TL;DR

Researchers have documented the first case of a Sjögren’s syndrome patient presenting with focal, non-diffuse kidney lesions typically associated with more aggressive, global disease. The study highlights how a common pulmonary infection can act as a critical "second hit," triggering cryoglobulinemic flares that severely damage kidney function.

What Problem Does This Paper Address?

Primary Sjögren’s syndrome (pSS) is an autoimmune disorder primarily known for causing dry eyes and mouth, but it can also attack the kidneys. When it does, it often manifests as MPGN—a pattern of glomerular injury characterized by the thickening of the kidney's filtering membranes.

Standard medical teaching suggests that primary MPGN is "diffuse," meaning it affects the majority of the kidney's filters (glomeruli) in a uniform, spherical way. While secondary MPGN (caused by other diseases like Lupus) can be focal or segmental, this specific "non-diffuse" pattern had never been documented in pSS-related cryoglobulinemic glomerulonephritis. This paper addresses the diagnostic challenge of identifying kidney involvement when the pathological "fingerprint" doesn't match the textbook definition.

Methods

The authors conducted a longitudinal case study of a 52-year-old woman. Their methodology relied on a multi-modal diagnostic approach:

  • Serological Testing: Monitoring antinuclear antibodies (ANA), rheumatoid factor (RF), and complement levels (C3/C4).
  • Cryoglobulin Analysis: Identifying Type II cryoglobulinemia.
  • Pathological Triangulation: The core of the study involved comparing three types of imaging from a renal biopsy:
  • Light Microscopy (LM): To observe the distribution of lesions (finding them in only 66.7% of glomeruli).
  • Immunofluorescence (IF): To identify the specific proteins (IgM and kappa light chains) depositing in the tissue.
  • Electron Microscopy (EM): To confirm the presence of subendothelial "block-shaped" electron-dense deposits, a hallmark of cryoglobulinemia.

Datasets

As this is a clinical case report, no large-scale datasets or machine-learning benchmarks were used. The "data" consists of the patient's 30-month clinical history, laboratory values, and biopsy imagery.

Key Insights and Ideas

  • Infection as a Trigger: The patient was stable for two years until a pulmonary infection occurred. The authors suggest that the infection increased rheumatoid factor (RF) levels, which in turn exacerbated the production of cryoglobulins, leading to an acute kidney injury (AKI).
  • The "Non-Diffuse" Exception: The most significant finding is that MPGN-like lesions were found in only ~67% of the glomeruli. Usually, clinicians expect a "diffuse" (global) pattern in these cases. This suggests that pSS-related kidney disease can present more subtly on light microscopy than previously thought.
  • Differential Diagnosis via Immunofluorescence: The study notes that while the kidney damage looked similar to Lupus Nephritis (LN), the absence of a "full house" pattern (where IgG, IgA, IgM, C3, and C1q are all present) and the dominance of IgM/kappa helped rule out Lupus and confirm pSS-related cryoglobulinemia.

Key Results

  • Clinical Recovery: Following a regimen of anti-infectives, methylprednisolone, and cyclophosphamide (12g total dose), the patient showed remarkable recovery.
  • Quantitative Markers:
    • Creatinine: Dropped from a peak of 327.3 µmol/L during the acute phase to 82.1 µmol/L at the 30-month follow-up (returning to normal range).
  • Proteinuria: Reduced from a dangerous 9.78 g/24h to being completely negative.
  • Complements: C3 and C4 levels normalized, indicating the autoimmune "fire" had been extinguished.

Limitations and Future Work

The primary limitation is the N=1 sample size. While this case provides a "proof of concept" for non-diffuse MPGN in pSS, it is impossible to determine how common this atypical presentation is across the broader patient population.

The authors suggest that clinicians should maintain a high index of suspicion for cryoglobulinemic GN in pSS patients who develop infections, even if initial biopsies don't show the classic "diffuse" damage. Future research is needed to establish whether "non-diffuse" lesions represent an early stage of the disease or a distinct clinical subtype.

Summary updated

Abstract

This case represents the first reported instance of non-diffuse MPGN with cryoglobulinemic GN secondary to pSS. Infection may serve as a key factor in exacerbating cryoglobulinemia and triggering cryoglobulinemic GN onset.
BibTeX
@inproceedings{duan2025primary,
  author = {Zhi-Yu Duan and Guangyan Cai and FengKun Chen and Xuanli Tang and Xu Zhang and Yali Ren and Yan Song},
  title = {{Primary Sjögren’s syndrome presenting with non-diffuse membranoproliferative glomerulonephritis-like lesions in cryoglobulinemic glomerulonephritis: a case report}},
  booktitle = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1610017},
}
Figure